Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease

Movement Disorders

Volumn 25, Issue 7, 2010, Pages 888-895

  Wild, Edward J ^a   Henley, Susie M D ^a   Hobbs, Nicola Z ^a   Frost, Chris ^a,b   MacManus, David G ^a   Barker, Roger A ^c   Fox, Nick C ^a   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Huntington's disease; Volumetric MRI; Whole brain atrophy

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MALE; NEUROBIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; ATROPHY; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POINT MUTATION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77951948907     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22969     Document Type: Article

References (31)

1. Aronin N, Chase K, Young C, et al. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron 1995;15:1193-1201.
2. Sathasivam K, Hobbs C, Turmaine M, et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999;8:813-822.
3. Björkqvist M, Wild EJ, Thiele J, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008;205:1869-1877.
4. Forno L, Norville R. Ultrastructure of the neostriatum in Huntington's and Parkinson's disease. Adv Neurol 1979;1:453-470.
5. Oliva D, Carella F, Savoiardo M, et al. Clinical and magnetic resonance features of the classic and akinetic-rigid variants of Huntington's disease. Arch Neurol 1993;50:17-19.
6. Gutekunst C-A, Li S-H, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999;19:2522-2534.
7. Henley SMD, Frost C, MacManus DG, Warner TT, Fox NC, Tabrizi SJ. Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 2006;67:694-696.
8. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
9. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65:745-747.
10. Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003;60:1615-1620.
11. Handley OJ, Naji JJ, Dunnett SB, Rosser AE. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci 2006;110:73-88.
12. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101:57-66.
13. Wild EJ, Tabrizi SJ. Predict-HD and the future of therapeutic trials. Lancet Neurol 2006;5:724-725.
14. Wild EJ, Tabrizi SJ. Biomarkers for Huntington's disease. Expert Opin Med Diagn 2008;2:47-62.
15. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997;16:623-629.
16. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 2005;65:119-124.
17. Fox NC, Black RS, Gilman S, et al. Effects of A-beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-1572.
18. Henley SMD, Wild EJ, Hobbs NZ, et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 2009;24:932-936.
19. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552-560.
20. The Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142.
21. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-1335.
22. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87-97.
23. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15-25.
24. Woods RP, Grafton ST, Holmes CJ, Cherry SR, Mazziotta JC. Automated image registration: I. General methods and intrasubject, intramodality validation. J Comput Assist Tomogr 1998;22:139-152.
25. Whitwell JL, Crum WR, Watt HC, Fox NC. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 2001;22:1483-1489.
26. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277.
27. Henley SMD, Wild EJ, Hobbs N, et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J Neurol 2009;256:203-212.
28. Duning T, Kloska S, Steinstrater O, Kugel H, Heindel W, Knecht S. Dehydration confounds the assessment of brain atrophy. Neurology 2005;64:548-550.
29. Fox N, Schott J. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet 2004;363:392-394.
30. Roos RA, Hermans J, Vegter-van der Vlis M, van Ommen GJ, Bruyn GW. Duration of illness in Huntington's disease is not related to age at onset. J Neurol Neurosurg Psychiatry 1993;56:98-100.
31. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008;79:874-880.